Healthcare
Teva Pharmaceutical Industries Limited(TEVJF)
Live Price
Offline$30.34
+0.00% today
1Y Change
+69.61%
Window
Jun 20, 2025 β May 26, 2026
- Market Cap
- $40.71B
- Revenue Growth
- +12.9%
- EPS Growth
- +184.8%
- Dividend Yield
- 0.0%
Coverage: 234 bars Β· Jun 20, 2025 β May 26, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Teva Pharmaceutical Industries Limited (TEVJF) is a Healthcare stock with a market cap of $40.71B and listed on OTC. The stock last traded around $30.34 and up 69.6% across the available one-year price window (Jun 20, 2025 β May 26, 2026). Baseline metrics include revenue growth of +12.9%, EPS growth of +184.8%, a dividend yield of 0.0%. What stands out right now is revenue +12.9%, EPS +184.8%, free cash flow +241.4% with operating margin 19.4% and ROIC 11.5%. Valuation is more restrained than many high-expectation growth names at P/E 25.7 and price/sales 2.3. Stock Foundry combines TEVJF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+12.9% vs +7.6% peer median
Operating Margin
Near sector median
+19.4% vs +19.4% peer median
P/E
Below sector median
25.7 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 29, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +12.9% and EPS at +184.8%, with operating margin around 19.4%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 29, 2026 | β | +0.0% | +0.0% | β |
2026 Jan 28, 2026 | +46.2% | +0.0% | +0.0% | +0.0% |
2025 Jul 30, 2025 | -60.6% | +0.0% | +0.0% | +2.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TEVJF
β
Normalized return
SPY
β
S&P 500
Excess Return
β
Relative to SPY
TEVJF Max Drawdown
-21.35%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TEVJF and SPY.
Company Overview
Teva Pharmaceutical Industries Limited
Other OTC
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
- Leadership
- Richard D. Francis
- IPO Date
- Jun 18, 2010
- Employees
- 37.0k
- Street Address
- 124 Dvora Haneviβa Street
- Mailing
- Tel Aviv, 6944020
- Region
- Tel Aviv, IL
- Reporting Currency
- USD
- Investor Line
- 972 3 914 8213
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 25.7
- EV/EBITDA
- 16.3
- Price/Sales
- 2.3
- Price/Book
- 4.9
Growth
- Revenue
- +12.9%
- EPS
- +184.8%
- Free Cash Flow
- +241.4%
Profitability
- Gross Margin
- 52.0%
- Operating Margin
- 19.4%
- Net Margin
- 9.0%
- ROE
- 20.8%
- ROIC
- 11.5%
Balance Sheet
- Debt/Equity
- 2.05
- Current Ratio
- 1.01
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.